Assessment of Flecainide to Lower the patent foramen Ovale closure risk of Atrial fibrillation or Tachycardia
American College of Cardiology
NOVEMBER 11, 2024
The goal of the AFLOAT trial was to compare the efficacy of flecainide compared with standard of care in preventing atrial fibrillation (AF) post-patent foramen ovale (PFO) closure.
Let's personalize your content